904 completed, 162 unknown, 157 terminated, 98 recruiting. 1465 Phase 2, 219 Phase 1, 150 Phase 3.
Follow Arthritis: new trials by email Literature Review of Arthritis trials Research Report on Arthritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid | Phase 1 / Phase 2 | Withdrawn | Crystal Lederhos Smith | 2028-07-15 | 2026-09-23 | |
| Efficacy and Safety of GNSC-001 Intra-articular Injection for Knee Osteoarthritis Gene Therapy GNSC-001, Placebo - Knee Arthritis Osteoarthritis, Knee Arthritis, Osteoarthritis | Phase 2 / Phase 3 | Not yet recruiting | Genascence Corporation | 240 | 2027-07-01 | 2026-09-21 |
| Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE) Exercise, Duloxetine, Placebo - Knee Osteoarthritis, Pain | Phase 2 | Not yet recruiting | VA Office of Research and Development | 102 | 2027-03-01 | 2026-06-16 |
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis ABBV-722, Upadacitinib - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | AbbVie | 250 | 2026-12-07 | 2026-10-29 |
| Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease Infliximab 0.1%, Loteprednol - Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis | Phase 2 | Not yet recruiting | Instituto de Oftalmología Fundación Conde de Valenciana | 38 | 2026-12-01 | 2026-06-26 |
| Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA) | Phase 2 | Not yet recruiting | Forward Therapeutics | 210 | 2026-12-01 | 2026-10-09 |
| Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren Syndrome exosomes derived from human umbilical cord mesenchymal stem cells, Mesenchymal Stem Cells (MSC), Placebo - Sjogren Syndrome, Xerostomia | Phase 2 | Not yet recruiting | Banu Erkal | 30 | 2026-12-01 | 2026-09-24 |
| Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis Dapagliflozin, Empagliflozin, Methotrexate - Rheumatoid Arthritis (RA) | Phase 2 | Not yet recruiting | Al-Azhar University | 90 | 2026-12-01 | 2026-10-08 |
| A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) MK-8690, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-11-23 | 2026-10-26 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis. ICM-203 - Osteoarthritis, Knee | Phase 1 / Phase 2 | Withdrawn | ICM Co. Ltd. | 2026-11-15 | 2026-09-08 | |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis inulin, Maltodextrin (Placebo) - Knee Osteoarthritis | Phase 2 | Not yet recruiting | Yale University | 84 | 2026-11-01 | 2026-07-07 |
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-10-30 | 2026-10-13 |
| Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis Placebo, Dapagliflozin (10mg Tab) - Rheumatoid Arthritis (RA | Phase 1 / Phase 2 | Not yet recruiting | Tanta University | 100 | 2026-10-30 | 2026-10-28 |
| Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera Ondansetron, Standard Cholera Care - Cholera (Disorder) | Phase 2 | Not yet recruiting | Public Interest Science Center | 120 | 2026-10-20 | 2026-10-19 |
| the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM - Rheumatoid Arthritis (RA), Manegmentof Rheumatoid Arthritis | Phase 2 / Phase 3 | Not yet recruiting | Ain Shams University | 50 | 2026-10-15 | 2026-10-06 |
| A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease Part A - Placebo for IBI355, Part B -Telitacicept, PartB -Placebo for Telitacicept - Sjögren's Disease | Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 198 | 2026-10-15 | 2026-09-23 |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 220 | 2026-10-14 | 2026-10-13 |
Showing 20 of 1465. Sign in to see all of them.
Arthritis, Rheumatoid (567) · Osteoarthritis, Knee (349) · Osteoarthritis (347) · Pain (78) · Sjogren's Syndrome (77) · Gout (71) · Arthritis, Psoriatic (64) · Spondylitis, Ankylosing (57) · Hyperuricemia (37) · Joint Diseases (36) · Inflammation (34) · Autoimmune Diseases (32) · Arthritis, Juvenile (31) · Osteoarthritis, Hip (30)
Musculoskeletal Diseases (1440) · Joint Diseases (1429) · Rheumatic Diseases (1288) · Skin and Connective Tissue Diseases (743) · Connective Tissue Diseases (676) · Immune System Diseases (672) · Autoimmune Diseases (643) · Osteoarthritis (224) · Pathological Conditions, Signs and Symptoms (224) · Bone Diseases (143) · Spinal Diseases (131) · Spondylitis (127) · Signs and Symptoms (126) · Spondylarthropathies (123)
Methotrexate (81) · Adalimumab (34) · Sodium Chloride (27) · tofacitinib (26) · Hyaluronic Acid (25) · Rituximab (24) · Saline Solution (20) · Abatacept (19) · Colchicine (18) · Febuxostat (18) · Naproxen (18) · Folic Acid (17) · Etanercept (16) · canakinumab (15) · Allopurinol (14)
Pfizer (42) · Novartis Pharmaceuticals (36) · Amgen (25) · AbbVie (22) · Eli Lilly and Company (22) · GlaxoSmithKline (22) · Bristol-Myers Squibb (16) · AstraZeneca (14) · Charite University, Berlin, Germany (14) · Pacira Pharmaceuticals, Inc (14) · Hoffmann-La Roche (13) · Janssen Research & Development, LLC (13) · Lakefront Biotherapeutics NV (13) · Merck Sharp & Dohme LLC (12) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (12)
United States (629) · Poland (219) · Germany (188) · Spain (148) · Canada (139) · Czechia (139) · Hungary (130) · United Kingdom (121) · China (108) · Mexico (102) · Russia (102) · France (86) · Belgium (81) · Bulgaria (79) · Argentina (76)
PMID 32816215, PMID 33127856, PMID 34870800, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 39192350, PMID 25047021, PMID 28143815, PMID 38958913, PMID 26275429, PMID 28941219, PMID 40194794, PMID 41807031, PMID 29463520, PMID 30842122, PMID 34041702, PMID 34706874, PMID 36205910, PMID 37453736, PMID 37747626, PMID 16911575, PMID 19404957, PMID 23254770, PMID 24476416, PMID 24699939, PMID 25035839, PMID 25925602, PMID 27156561, PMID 27338778, PMID 27455842, PMID 27747583, PMID 28622463, PMID 29076110, PMID 30032191, PMID 30203101, PMID 30376130, PMID 31194885, PMID 31512746, PMID 31610021, PMID 31912462, PMID 32951150, PMID 33254235, PMID 33420185, PMID 35789257, PMID 35833532, PMID 35931879, PMID 36178584, PMID 39495154
2016 (20), 2009 (19), 2014 (16), 2015 (15), 2025 (14), 2017 (10), 2018 (10), 2019 (10), 2023 (8), 2008 (7), 2004 (3), 2005 (3), P60AR020582 (2), 1UG3AR077748-01 (1), 268200700015C-2-0-0 (1)